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Summary
Background Stroke thrombolysis with alteplase is currently recommended 0–4·5 h after stroke onset. We aimed to 
determine whether perfusion imaging can identify patients with salvageable brain tissue with symptoms 4·5 h or 
more from stroke onset or with symptoms on waking who might benefit from thrombolysis.
Methods In this systematic review and meta-analysis of individual patient data, we searched PubMed for randomised 
trials published in English between Jan 1, 2006, and March 1, 2019. We also reviewed the reference list of a previous 
systematic review of thrombolysis and searched ClinicalTrials.gov for interventional studies of ischaemic stroke. 
Studies of alteplase versus placebo in patients (aged ≥18 years) with ischaemic stroke treated more than 4·5 h after 
onset, or with wake-up stroke, who were imaged with perfusion-diffusion MRI or CT perfusion were eligible for 
inclusion. The primary outcome was excellent functional outcome (modified Rankin Scale [mRS] score 0–1) at 
3 months, adjusted for baseline age and clinical severity. Safety outcomes were death and symptomatic intracerebral 
haemorrhage. We calculated odds ratios, adjusted for baseline age and National Institutes of Health Stroke Scale score, 
using mixed-effects logistic regression models. This study is registered with PROSPERO, number CRD42019128036.
Findings We identified three trials that met eligibility criteria: EXTEND, ECASS4-EXTEND, and EPITHET. Of the 
414 patients included in the three trials, 213 (51%) were assigned to receive alteplase and 201 (49%) were assigned to 
receive placebo. Overall, 211 patients in the alteplase group and 199 patients in the placebo group had mRS assessment 
data at 3 months and thus were included in the analysis of the primary outcome. 76 (36%) of 211 patients in the 
alteplase group and 58 (29%) of 199 patients in the placebo group had achieved excellent functional outcome at 
3 months (adjusted odds ratio [OR] 1·86, 95% CI 1·15–2·99, p=0·011). Symptomatic intracerebral haemorrhage was 
more common in the alteplase group than the placebo group (ten [5%] of 213 patients vs one [<1%] of 201 patients in 
the placebo group; adjusted OR 9·7, 95% CI 1·23–76·55, p=0·031). 29 (14%) of 213 patients in the alteplase group 
and 18 (9%) of 201 patients in the placebo group died (adjusted OR 1·55, 0·81–2·96, p=0·66).
Interpretation Patients with ischaemic stroke 4·5–9 h from stroke onset or wake-up stroke with salvageable brain 
tissue who were treated with alteplase achieved better functional outcomes than did patients given placebo. The rate 
of symptomatic intracerebral haemorrhage was higher with alteplase, but this increase did not negate the overall net 
benefit of thrombolysis.
Funding None.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Introduction
Current guidelines recommend thrombolysis with intra­
venous alteplase for acute ischaemic stroke up to 4·5 h 
from stroke onset on the basis of individual patient data 
from randomised trials that included patients according 
to non­contrast CT brain and clinical criteria.1 These 
criteria exclude a substantial proportion of patients who 
present more than 4·5 h after stroke onset or who have 
unknown onset (eg, wake­up stroke). The WAKE­UP trial2 
demonstrated the benefit of intravenous thrombolysis 
with alteplase in patients with stroke symptoms on waking 
by identifying an MRI pattern suggestive of stroke with an 
onset of less than 4·5 h. This method of selection increases 
the proportion of patients eligible for treatment, but other 
research3 showed that this selection approach only 
identifies around 62% of patients who are within the 
0–4·5 h time window. Furthermore, this approach 
excludes patients who might have salvageable brain tissue, 
despite pres enting more than 4·5 h after stroke onset.
An alternative approach is to use CT perfusion or 
perfusion­diffusion MRI to identify patients with poten­
tially salvageable brain tissue, regardless of time from 
Published Online 
May 22, 2019 
http://dx.doi.org/10.1016/
S0140-6736(19)31053-0
See Online/Comment 
http://dx.doi.org/10.1016/ 
S0140-6736(19)31095-5
*Contributed equally
†Contributed equally
‡Investigators listed in the 
appendix
Department of Medicine and 
Neurology, Melbourne Brain 
Centre (Prof B C V Campbell PhD, 
Prof M W Parsons PhD, 
Prof L Churilov PhD, N Yassi PhD, 
G Sharma MCA, A Bivard PhD, 
Prof B Yan DMedSci, 
Prof S M Davis MD, 
Prof G A Donnan MD) 
and Department of Radiology 
(Prof P M Desmond MD, 
Prof B Yan, 
Prof P J Mitchell MMed), 
Royal Melbourne Hospital, 
and Florey Institute of 
Neuroscience and Mental 
Health (Prof B C V Campbell, 
Prof H Ma PhD, 
Prof C F Bladin MD, N Yassi, 
Prof V Thijs PhD, 
Prof G A Donnan), University 
of Melbourne, Melbourne, VIC, 
Australia; Department of 
Medicine, School of Clinical 
Science (Prof H Ma) and 
Department of Neurosciences, 
Eastern Health and Eastern 
Health Clinical School 
(Prof H M Dewey PhD, 
Prof C F Bladin), Monash 
University, Melbourne, VIC, 
Australia; Department of 
Neurology (Prof P A Ringleb MD, 
Prof W Hacke MD) and 
Department of Neuroradiology 
(Prof M Bendszus MD, 
J A R Pfaff MD), Ruprecht Karls 
University Heidelberg, 
Heidelberg, Germany; 
Department of Medicine 
(Prof L Churilov) and 
Department of Neurology
Articles
2 www.thelancet.com   Published online May 22, 2019   http://dx.doi.org/10.1016/S0140-6736(19)31053-0
(Prof V Thijs), Austin Health, 
and Department of Medicine, 
Western Hospital, Melbourne 
Medical School 
(Prof T Wijeratne MD), 
University of Melbourne, 
Melbourne, VIC, Australia; 
Department of Neurology, 
Priority Research Centre for 
Brain and Mental Health 
Research, John Hunter Hospital, 
University of Newcastle, 
Newcastle, NSW, Australia 
(Prof C R Levi MBBS); Graduate 
Institute of Clinical Medical 
Science, China Medical 
University, Taichung, Taiwan 
(Prof C Hsu PhD); Department of 
Neurology, Royal Adelaide 
Hospital, Adelaide, SA, 
Australia (T J Kleinig PhD); 
Department of Neurology, 
Faculty of Medicine Mannheim, 
University of Heidelberg, 
Mannheim, Germany 
(Prof M Fatar MD); Department 
of Neurology, Hospital CHU 
Lille, Lille, France 
(Prof D Leys MD); Department 
of Neurology, Hospital 
Vall d´Hebron, University of 
Barcelona, Barcelona, Spain 
(Prof C Molina MD); Department 
of Neurology, Western Health, 
Sunshine Hospital, Melbourne, 
VIC, Australia (Prof T Wijeratne); 
Department of Neurology, 
Helsinki University Hospital, 
Helsinki, Finland (S Curtze PhD); 
Department of Neurology, 
Auckland City Hospital, 
University of Auckland, 
Auckland, New Zealand 
(Prof P A Barber PhD); Prince of 
Wales Clinical School, 
University of New South Wales, 
Sydney, NSW, Australia 
(Prof K S Butcher PhD); Division 
of Neurology, University of 
Alberta, Edmonton, AB, Canada 
(Prof K S Butcher); Department 
of Neurology, Singapore 
General Hospital, National 
Neuroscience Institute, 
Singapore (D A De Silva FRCP); 
Department of Neurology, 
University of 
Erlangen-Nuremberg, Erlangen, 
Germany (Prof S Schwab MD); 
Department of Neurology and 
Neurogeriatry, Johannes 
Wesling Medical Centre 
Minden, University Hospital of 
Ruhr-University Bochum, 
Bochum, Germany 
(Prof P D Schellinger MD); 
Department of Neurology, 
Girona University Hospital, 
Biomedical Research Institute 
of Girona, Girona, Spain 
(Prof J Serena PhD); and
stroke onset. Reperfusion beyond 4·5 h after stroke onset 
is associated with favourable clinical outcomes in patients 
with perfusion mismatch.4–7 Patient selection on the basis 
of perfusion mismatch to identify treatment­responsive 
patients with salvageable brain tissue who have presented 
more than 4·5 h after stroke onset has been established for 
endovascular throm bectomy in patients with large vessel 
occlusion 6–24 h after the time they were last known to be 
well.8–10 Intravenous thrombolysis could potentially treat a 
broader range of patients.
We did a meta­analysis of individual patient data to test 
the hypothesis that intravenous alteplase improves 
functional outcomes compared with placebo in patients 
with ischaemic stroke 4·5–9 h after onset or wake­up 
stroke who were imaged with CT perfusion or perfusion­
diffusion MRI.
Methods
Search strategy and selection criteria
We did a systematic search of PubMed for randomised 
controlled trials published in English between Jan 1, 2006, 
and March 1, 2019, using the search terms “stroke” 
AND either “randomized” OR “randomised” AND either 
“thrombolysis” OR “alteplase” OR “tPA”. Trials of 
intravenous alteplase versus placebo in adults (aged 
≥18 years) with hemispheric ischaemic stroke more 
than 4·5 h after stroke onset or wake­up stroke who 
had pretreatment imaging with CT perfusion or 
perfusion­diffusion MRI were eligible for inclusion. 
Full eligibility criteria for all trials are described in 
the appendix. We also reviewed the reference list of a 
previous systematic review of thrombolysis1 and searched 
ClinicalTrials.gov for interventional studies of ischaemic 
stroke using the keywords thrombolysis and alteplase. 
Patients with available data on age, pretreatment National 
Institutes of Health Stroke Scale (NIHSS) score, and 
modified Rankin Scale (mRS) score at 3 months were 
eligible for inclusion in the meta­analysis. Two reviewers 
(BCVC and NY) independently assessed articles for 
inclusion.
The management committees of all included trials 
agreed to share individual patient­level data for the 
purposes of this meta­analysis. Ethical approval was 
obtained at all participating sites for all included trials, 
and informed consent was obtained from all participants 
or their legal representative. The protocol for this study 
was prespecified and followed PRISMA guidelines 
(appendix).
Data analysis
A statistician (LC) merged the databases of the included 
studies on the basis of data fields prespecified in the 
protocol. We extracted data on treatment, age, sex, 
pretreatment NIHSS score, geographical location, time 
Research in context
Evidence before this study
We did a systematic review of PubMed between Jan 1, 2006, 
and March 1, 2019, for randomised controlled trials published in 
English using the search terms “stroke” AND either “randomized” 
OR “randomised” AND either “thrombolysis” OR “alteplase” OR 
“tPA”. In the EXTEND trial, patients randomly assigned to 
alteplase after automated CT or MRI perfusion imaging were 
found to have improvement in excellent functional outcome 
compared with placebo; however, the strength and precision of 
findings were limited by the modest sample size (n=225). 
The ECASS4-EXTEND trial randomly assigned 119 patients after 
visual assessment of perfusion-diffusion MRI, and found no 
statistically significant benefits of alteplase. EPITHET was a 
phase 2 randomised trial of alteplase 3–6 h after stroke onset 
using perfusion-diffusion MRI, in which 70 patients were treated 
within the 4·5–6 h time window. Although the overall results of 
the trial were neutral, in patients treated 4·5–6 h after stroke 
onset, thrombolysis reduced relative infarct growth and 
increased the rate of reperfusion. Effective reperfusion was 
associated with good neurological and functional outcome.
Added value of this study
This systematic review and meta-analysis of individual patient 
data quantifies the benefits and risks of intravenous alteplase 
for patients with ischaemic stroke beyond 4·5 h from when 
they were last known to be well. The proportion of patients 
with excellent functional outcome (return to all usual activities) 
at 3 months was significantly higher in the alteplase group than 
the placebo group. The proportion of patients with functional 
improvement (≥1 point reduction in modified Rankin Scale 
score) at 3 months was also significantly higher in the alteplase 
group than the placebo group. Although a higher proportion of 
patients in the alteplase group had symptomatic intracerebral 
haemorrhage than the placebo group, no significant difference 
in mortality was observed between the groups. Patients with a 
perfusion imaging mismatch (indicating salvageable brain 
tissue) detected with automated software in core laboratory 
analysis had significant benefit from alteplase, whereas those 
without perfusion mismatch detected by automated software 
did not, although this comparison was underpowered and 
formal statistical interaction was not demonstrated.
Implications of all the available evidence
Patients with ischaemic stroke 4·5–9 h after stroke onset or 
with wake-up stroke with evidence of salvageable brain tissue 
using CT perfusion or perfusion-diffusion MRI who were given 
intravenous alteplase have improved functional outcomes 
compared with those given placebo. Patients given alteplase 
had an increased risk of symptomatic intracerebral 
haemorrhage, consistent with the findings from previous trials 
of alteplase for stroke, but this increased risk does not offset 
the net benefit of thrombolysis. The benefit to risk ratio seems 
to be larger in patients who meet automated perfusion 
mismatch criteria.
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post stroke onset or after wake­up stroke, atrial fibril­
lation, hypertension, diabetes, smoking status, NIHSS 
score at 72 h, mRS at 3 months, and symptomatic 
intracerebral haemorrhage.
For this meta­analysis, the prespecified primary outcome 
was the proportion of patients with excellent functional 
outcome (mRS score 0–1 [return to all usual activities]) 
at 3 months, adjusted for pretreatment clinical severity 
(NIHSS score) and age. Secondary outcomes were 
functional improve ment (≥1 point reduction in mRS 
score [ordinal shift analysis]), with mRS categories 5 
and 6 merged, at 3 months, func tional independence 
(mRS score 0–2) at 3 months, and early neurological 
improvement (reduction of ≥8 points on NIHSS or 
reaching NIHSS score 0–1) at 72 h. All secondary outcomes 
were adjusted for pretreat ment NIHSS score and age. 
Safety outcomes were symptomatic intracerebral haemor­
rhage defined as parenchymal haemorrhage type 2 (blood 
clot occupying >30% of the infarcted territory with 
substantial mass effect) within 36 h of treatment, combined 
with neurological deterioration of 4 or more NIHSS points, 
or death.11 Death due to any cause at 3 months was adjusted 
for age and pretreatment NIHSS score.
A full description of the analyses is provided in 
the prespecified statistical analysis plan (appendix). 
Statistical analysis was done using Stata (version 15). 
Qualitative assessment of between trial differences 
including patient eligibility and assessment of bias are 
shown in the appendix.
Our meta­analysis followed a one­stage approach. To 
account for between­trial variance we used mixed­effects 
logistic regression models with trial and trial­by­treatment 
interaction terms incorporated as random effects in all 
models. We analysed the primary outcome and other 
dichotomous secondary and safety outcomes using 
mixed­effects logistic regression models, adjusted for 
baseline age and NIHSS score, to estimate adjusted odds 
ratios (ORs) and 95% CIs. Functional improvement was 
analysed using mixed­effects ordinal logistic regression 
(with mRS 5 and 6 categories merged), adjusted for 
baseline age and NIHSS score. We did preplanned 
subgroup analyses to assess the effects of age (≤75 vs 
>75 years and ≤80 vs >80 years), baseline stroke severity 
(NIHSS score ≤10 vs NIHSS score >10), time to treatment 
(>4·5–6·0 h, >6·0–9·0 h, or wake­up stroke), geographical 
region (Australia and New Zealand, Europe, or Asia), and 
presence of any large vessel occlusion. Large vessel 
occlusion was defined as occlusion of the internal carotid 
artery or middle cerebral artery (M1 or proximal M2), 
based on central imaging review, to identify patients 
who would be eligible for endovascular thrombectomy 
according to current clinical practice. Analyses were 
repeated in the prespecified subgroup of patients who 
met automated perfusion mismatch criteria. For all 
subgroup analyses, treatment­by­subgroup interactions 
were tested by including multiplicative interaction terms 
in respective regression models.
For analysis of the prespecified subgroup with 
perfusion mismatch determined by automated 
processing software, CT perfusion and perfusion­
diffusion MRI imaging data for individual patients were 
uniformly reprocessed using RAPID (version 4.6; 
iSchemaView, Menlo Park, CA, USA) as described 
previously.8,9 Although all patients in the EXTEND 
trial12,13 were judged to meet automated mismatch criteria 
by the enrolment site, central analysis of perfusion 
mismatch was done to exclude imaging artefacts and to 
account for software evolution over the 8 years of trial 
recruitment. All automated output was visually verified 
and artefacts removed by a stroke neurologist with 
extensive neuroimaging analysis expe rience, masked to 
treatment allocation and all other imaging and clinical 
information. For CT perfusion, irreversibly injured 
ischaemic core was defined as a relative cerebral blood 
flow of less than 30% of normal brain blood flow.14 For 
diffusion MRI, ischaemic core was defined as an 
apparent diffusion coefficient of less than 620 μm²/s.15 
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Placebo 
(n=201)
Alteplase 
(n=213)
Age, years 72·0 (12·3) 73·2 (12·2)
Sex
Men 116 (58%) 119 (56%)
Women 85 (42%) 94 (44%)
NIHSS score 10 (6–16) 12 (7–17)
Previously diagnosed atrial fibrillation 63 (31%) 79 (37%)
History of hypertension 134 (67%) 159 (75%)
History of diabetes 41 (20%) 49 (23%)
History of smoking 62/165 (38%) 58/179 (32%)
Geographical region
Australia or New Zealand 110 (55%) 121 (57%)
Europe 67 (33%) 69 (32%)
Asia 24 (12%) 23 (11%)
Time from stroke onset to randomisation
>4·5–6·0 h 49 (24%) 58 (27%)
>6·0–9·0 h 48 (24%) 50 (24%)
Wake-up stroke 104 (52%) 105 (49%)
Imaged with CT perfusion 96 (48%) 100 (47%)
Imaged with perfusion-diffusion 
MRI
105 (52%) 113 (53%)
Time from stroke onset* to initiation 
of intravenous therapy, min
413 (353–480) 417 (346–485)
Time from last known to be well to 
initiation of intravenous therapy, min
487 (360–655) 471 (355–649)
Large vessel occlusion 122/198 (62%) 124/205 (60%)
Ischaemic core volume† at initial 
imaging
8·1 (0–20·4) 8·0 (0–25·3)
Perfusion lesion volume‡ at initial 
imaging
64·3 
(33·2–97·0)
63·9 
(27·9–117·2)
Data are mean (SD), n (%), median (IQR), or n/N (%). NIHSS=National Institutes of 
Health Stroke Scale. *Onset time measured as the midpoint of falling asleep and 
waking with stroke symptoms for patients with wake-up stroke. †Relative 
cerebral blood flow less than 30% of normal blood flow. ‡Time to maximum >6 s.
Table 1: Baseline characteristics of all patients
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The volume of critically hypoperfused tissue (the 
penumbra and core combined) was estimated using CT 
perfusion or perfusion MRI with a time to maximum 
threshold of more than 6 s.16 Time to maximum relates 
to the time delay in tissue enhancement after a bolus 
of intravenous contrast is given. Mismatch volume 
(ie, estimated penumbral volume) was defined as 
critically hypoperfused tissue volume minus ischaemic 
core volume. Mismatch ratio was defined as critically 
hypoperfused tissue volume divided by ischaemic core 
volume. Patients with a mismatch ratio greater than 1·2, 
a mismatch volume greater than 10 mL, and an 
ischaemic core volume less than 70 mL were considered 
to have perfusion mismatch. This study is registered 
with PROSPERO, number CRD42019128036.
Role of the funding source
There was no funding source for this study. The funders 
of the component EXTEND, ECASS4­EXTEND, and 
EPITHET studies had no role in study design, data 
collection, data analysis, data interpretation, or the 
writing of this report. The corresponding author had 
full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Our search strategy identified three trials that met the 
eligibility criteria: EXTEND,12,13 ECASS4­EXTEND,17,18 and 
EPITHET.5 The three included trials compared intra­
venous alteplase with placebo (0·9 mg/kg, maximum 
90 mg delivered as a 10% bolus and 90% infusion over 
1 h). The phase 3 EXTEND randomised controlled trial12,13 
compared alteplase with placebo in patients 4·5–9·0 h 
from stroke onset and patients with wake­up stroke using 
automated CT perfusion or MRI perfusion­diffusion 
mismatch selection. EXTEND recruited patients from 
Australasia, Taiwan, and Finland. The trial was terminated 
early due to loss of equipoise after the results of the 
WAKE­UP trial,2 but showed that higher proportions of 
patients achieved excellent functional outcome with 
alteplase compared with placebo administered 4·5–9 h 
after onset or within 9 h of the midpoint of falling asleep 
and waking with stroke symptoms. The European 
ECASS4­EXTEND trial17,18 used the same clinical eligibility 
criteria as EXTEND but used visual assessment of MRI 
perfusion­diffusion imaging. ECASS4­EXTEND was 
terminated early due to reduced recruitment following 
the positive trials8,9 of thrombectomy in the 6–24 h 
treatment window. The trial demonstrated no significant 
benefit in the alteplase group compared with placebo. 
The phase 2 EPITHET trial4 randomly assigned patients 
to alteplase or placebo within 3–6 h of stroke onset after 
perfusion­diffusion MRI, which was processed offline to 
determine the presence of perfusion mismatch. Only 
patients treated 4·5–6·0 h after stroke onset in EPITHET 
were included in our meta­analysis. No significant 
differences in the primary outcome of geometric mean 
infarct growth were identified between treatment groups. 
However, alteplase increased reperfusion, which, in turn 
was associated with reduced infarct growth and improved 
clinical outcomes.19
Of the 414 patients included in the three trials (mean 
age 73 years [SD 12·2]), 213 (51%) patients were assigned 
to receive alteplase and 201 (49%) to receive placebo. 
Baseline characteristics were largely balanced between 
the two groups (table 1); however, initial stroke severity 
was non­significantly worse in the alteplase group than 
the placebo group (median NIHSS score 12 [IQR 7–17] vs 
10 [6–16]). Most patients were recruited from Australia 
or New Zealand, followed by Europe and Asia. Approxi­
mately half of all included patients had wake­up stroke 
(n=105 in the alteplase group; n=104 in the placebo 
group). The median time from when the patient was last 
known to be well to treatment in patients with wake­up 
stroke was 10 h 42 min (IQR 8 h 40 min–12 h 20 min). 
Overall, of the 403 patients with assessable angiographic 
imaging, 246 (61%) had large vessel occlusion that would 
potentially be amenable to endovascular thrombectomy. 
Figure 1: mRS scores at 3 months for all patients
mRS=modified Rankin Scale.
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mRS score
Placebo 
(n=201)
Alteplase 
(n=213)
Odds ratio* 
(95% CI)
p value
Primary outcome
Excellent functional outcome 
(mRS score 0–1) at 3 months
58/199 (29%) 76/211 (36%) 1·86 (1·15–2·99) 0·01
Secondary outcomes
Functional improvement in mRS 
score at 3 months†
NA NA 1·60 (1·12–2·27) 0·009
Functional independence 
(mRS score 0–2) at 3 months
87/199 (44%) 103/211 (49%) 1·74 (1·08–2·81) 0·02
Early neurological improvement 
at 72 h‡
31/197 (16%) 58/206 (28%) 2·54 (1·51–4·27) <0·0001
Safety outcomes
Death at 3 months 18/201 (9%) 29/213 (14%) 1·55 (0·81–2·97) 0·19
Symptomatic intracerebral 
haemorrhage§
1/201 (<1%) 10/213 (5%) 9·70 (1·23–76·55) 0·03
Data are n/N (%). mRS=modified Rankin Scale. NIHSS=National Institutes of Health Stroke Scale. NA=not applicable. 
*Adjusted for baseline age and NIHSS. †Reduction of ≥1 point in mRS score (with mRS categories 5 and 6 merged), 
analysed using ordinal logistic regression. ‡Reduction of ≥8 points on NIHSS or reaching NIHSS score 0–1 at 72 h. 
§Within 36h of treatment. 
Table 2: Study outcomes in all patients
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However, 97% of patients (403 of 414) were recruited 
before guideline changes made in February, 2018, 
recommended thrombectomy in the 6–24 h window and 
consideration of thrombectomy was an exclusion 
criterion in the three trials included. The median 
perfusion mismatch was 47 mL (IQR 17–85) with a 
median volume of critical hypoperfusion of 64 mL 
(30–109) and relatively small core of median volume 
8 mL (0–22).
Of the 414 patients included in the three trials, 
211 patients in the alteplase group and 199 patients in the 
placebo group had mRS data available at 3 months and 
thus were included in the analysis of the primary 
outcome. 76 (36%) of 211 patients in the alteplase group 
achieved the primary outcome of excellent functional 
outcome (mRS score 0–1) at 3 months compared with 
58 (29%) of 199 patients in the placebo group (adjusted 
odds ratio [OR] 1·86, 95% CI 1·15–2·99, p=0·011; 
figure 1, table 2). The proportion of patients achieving 
functional improvement and functional independence at 
3 months, and the proportion of patients with early 
neurological improvement at 72 h was significantly 
higher in the alteplase group than the placebo group 
(table 2). Prespecified subgroup analyses for the primary 
outcome are shown in figure 2 and subgroup analyses 
for additional outcomes are shown in the appendix.
The number of patients with symptomatic intracerebral 
haemorrhage was significantly higher in the alteplase 
group than the placebo group (ten [5%] of 213 patients vs 
one [<1%] of 201 patients, adjusted OR 9·7, 95% CI 
1·23–76·55, p=0·031). This included one patient with 
haemorrhagic transformation on the pretreatment CT 
scan (a protocol violation). However, no significant dif­
ferences were identified in mortality between the alteplase 
and placebo groups (29 [14%] of 213 patients vs 18 [9%] of 
201 patients, adjusted OR 1·55, 95% CI 0·81–2·96, 
p=0·19; table 2). All deaths are described in the appendix. 
Four deaths occurred in the first week after alteplase 
treatment due to symptomatic intracerebral haemorrhage 
related to treatment. One death in the alteplase group due 
to remote intracerebral haemorrhage that occurred on 
day 4 was attributed to heparin and warfarin admin­
istration. An additional death in the alteplase group 
occurred on day 77 due to pneumonia in a patient who 
had symptomatic intracerebral haemorrhage on day 1. 
42 (90%) of 47 deaths were unrelated to treatment. No 
303
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1·87 (0·96–3·64)
1 2 4 80·5 160·125 64 256
0·41
Large vessel occlusion
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Time strata (h)
NIHSS
Age (years) 
Age (years) 
Study
Overall
Yes
No
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>75
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EPITHET
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EXTEND
Large vessel occlusion
Region
Time strata (h)
NIHSS
Age (years) 
Age (years) 
Study
Overall
Yes
No
Europe
Asia
Australia or New Zealand
Wake-up stroke
6–9
4·5–6
>10
≤10
>80
≤80
>75
≤75
EPITHET
ECASS-4
EXTEND
410
244
155
133
 47
230
209
 97
104
235
175
140
270
211
199
 69
116
225
1·86 (1·15–2·99)
1·74 (0·89–3·38)
1·93 (0·96–3·89)
2·30 (0·99–5·33)
4·21 (0·83–21·51)
1·47 (0·78–2·77)
1·56 (0·81–3·02)
2·27 (0·83–6·24)
2·19 (0·82–5·85)
1·01 (0·49–2·06)
2·92 (1·53–5·58)
1·54 (0·62–3·83)
2·00 (1·14–3·49)
1·90 (0·93–3·89)
1·81 (0·95–3·43)
2·28 (0·71–7·35)
1·68 (0·67–4·22)
1·88 (0·99–3·59)*
1 20·5 40·25 8 16
Odds ratio (95% CI)n
0·60
pinteraction Odds ratio (95% CI)n pinteraction
Favours placebo Favours alteplase Favours placebo Favours alteplase
0·66
0·39
0·87
0·03
0·58
0·99
0·99
0·30
0·38
0·15
0·91
0·69
A All patients B Patients with perfusion mismatch
Figure 2: Subgroup analyses
Forest plots for the primary outcome of excellent functional outcome (modified Rankin Scale 0–1) in all patients (A) and patients with automated perfusion mismatch (B). Proportion of patients by 
treatment group for each subgroup are detailed in the appendix. NIHSS=National Institutes of Health Stroke Scale score. *Prespecified analysis of primary outcome for EXTEND trial used modified 
Poisson regression (adjusted risk ratio [for modified Rankin Scale score 0–1] 1·44, 95%CI 1·01–2·06; p=0·04).
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significant differences were identified in the proportion 
of patients with combined mRS scores of 5 or 6 (death 
and requirement for constant nursing care): 48 (23%) of 
211 patients in the alteplase group versus 41 (21%) of 
199 patients in the placebo group (adjusted OR 1·03, 
95% CI 0·62–1·74, p=0·897).
Central adjudication of perfusion mismatch status 
using automated RAPID software was possible in 
405 patients (raw imaging data were not available for 
six patients in the alteplase group and three patients in 
the placebo group). After central adjudication of perfusion 
mismatch status in these 405 patients, 304 patients had 
perfusion mismatch (152 [73%] of 207 patients in the 
alteplase group and 152 [77%] of 198 patients in the 
placebo group). Baseline characteristics of patients with 
automated perfusion mismatch were balanced between 
the groups (table 3). Among the 303 patients with 
automated perfusion mismatch who had available mRS 
scores at 3 months, the proportion of patients who 
achieved excellent functional outcome was higher in the 
alteplase group than the placebo group (55 [36%] of 
152 patients vs 39 [26%] of 151 patients; adjusted OR 2·06, 
95% CI 1·17–3·62, p=0·012; figure 3, table 4), and the 
point estimate of the effect size was larger in this 
subgroup analysis than the intention­to­treat analysis. 
Among patients without mismatch, no significant 
differences were observed in the proportion of patients 
who achieved excellent functional outcome between 
the alteplase and placebo groups (adjusted OR 1·22, 
95% CI 0·48–3·10, p=0·68; treatment by mismatch status 
interaction p=0·43). Similarly, among patients with 
mismatch, significant improvements in all secondary 
outcomes were observed in the alteplase group (table 4), 
whereas no significant differences were identified 
between the treatment groups among patients without 
mismatch (appendix). Safety outcomes in patients with 
perfusion mismatch were similar to those for all patients. 
Among patients with perfusion mismatch, the proportion 
of patients with an mRS score of 5 or 6 in the alteplase 
and placebo groups was similar (34 [23%] of 152 patients 
vs 36 [23%] of 151 patients; adjusted OR 0·83, 95% CI 
0·46–1·53, p=0·557).
Discussion
This meta­analysis of pooled individual patient­level data 
has shown that thrombolysis with intravenous alteplase 
in patients with acute ischaemic stroke 4·5–9 h after 
stroke onset or wake­up stroke, who were imaged with 
CT perfusion or perfusion­diffusion MRI, improves 
functional outcomes compared with placebo. The 
frequency of symptomatic intracerebral haemorrhage 
was around 4% higher in the alteplase group than the 
placebo group, which is consistent with the results of 
previous trials1 of alteplase 0–4·5 h after stroke. However, 
this did not negate the benefit of alteplase in ordinal 
analysis of the mRS, which accounts for transitions 
across the disability spectrum. Mortality was not 
significantly increased with alteplase and the proportion 
of patients who had an mRS score of 5 or 6 (ie, dead or 
requiring nursing home care) did not differ significantly 
between groups. Although no statistically significant 
interaction was identified between mismatch status and 
treatment effect, the benefit of alteplase in terms of 
functional outcome and independence, and neurological 
improvement was significant in patients who met 
automated perfusion mismatch criteria, but did not 
reach statistical significance in patients without perfusion 
mismatch.
The benefits of alteplase observed in this analysis 
compare favourably with those reported within 4·5 h of 
stroke onset. The adjusted OR for achieving an mRS score 
0–1 among all patients was 1·86 (95% CI 1·15–2·99) and 
2·06 (1·17–3·62) for patients with automated perfusion 
mismatch, compared with an adjusted OR of 1·75 
Placebo (n=152) Alteplase (n=152)
Age, years 72·1 (12·3) 73·2 (13·1)
Sex
Men 91 (60%) 86 (57%)
Women 61 (40%) 66 (43%)
NIHSS score 11 (7–17) 12 (7–17)
Previously diagnosed atrial 
fibrillation
53 (35%) 60 (40%)
History of hypertension 95 (63%) 113 (74%)
History of diabetes 28 (19%) 37 (24%)
History of smoking 52/119 (44%) 40/121 (33%)
Geographical region
Australia or New Zealand 91 (60%) 89 (59%)
Europe 40 (26%) 43 (28%)
Asia 21 (14%) 20 (13%)
Stroke onset to randomisation time
>4·5–6·0 h 31 (20%) 33 (22%)
>6·0–9·0 h 37 (24%) 37 (24%)
Wake-up stroke 84 (55%) 82 (54%)
Imaged with CT perfusion 90 (59%) 89 (59%)
Imaged with 
perfusion-diffusion MRI
62 (41%) 63 (41%)
Time from stroke onset* to 
initiation of intravenous 
therapy, min
422 (355–492) 425 (351–490)
Time from last known to be 
well to initiation of 
intravenous therapy, min
503 (374–657) 489 (374–670)
Large vessel occlusion 113/152 (74%) 107/151 (71%)
Ischaemic core volume† at 
initial imaging
8·9 (0–20·0) 6·2 (0–22·3)
Perfusion lesion volume‡ at 
initial imaging
75·1 (47·0–104·9) 74·0 (40·2–117·2)
Data are mean (SD), n (%), median (IQR), or n/N (%). NIHSS=National Institutes of 
Health Stroke Scale. *Onset time measured as the midpoint of falling asleep and 
waking with stroke symptoms for patients with wake-up stroke. †Relative 
cerebral blood flow less than 30% of normal blood flow. ‡Time to maximum >6 s.
Table 3: Baseline characteristics of patients with automated perfusion 
mismatch
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(1·35–2·27) for alteplase administered 0–3 h from stroke 
onset and 1·26 (1·05–1·51) for alteplase administered 
3–4·5 h from stroke onset, as reported previously.1 The 
absolute increase in the proportion of patients who 
achieved excellent functional outcome in this pooled 
analysis was 7% higher in the alteplase group than 
the placebo group (10% in patients with perfusion mis­
match). However, these unadjusted proportions are likely 
to underestimate the true benefit since there was a trend 
towards older age and greater clinical severity in the 
patients given alteplase. By comparison, alteplase admin­
istered 0–3 h after stroke onset improved excellent 
functional outcome by 9·8%. This reduced to 5·2% when 
administered at 3–4·5 h.1 In the WAKE­UP trial,2 which 
administered alteplase based on MRI evidence of onset at 
less than 4·5 h, the unadjusted improvement in excellent 
outcome was 11·5% and the adjusted OR was 1·61 
(95% CI 1·09–2·36). The treatment effect with alteplase 
was numerically lower than that observed with 
endovascular thrombectomy (18% difference in mRS 
score 0–1).8,9 This difference might reflect the more 
effective reperfusion achieved with endovascular throm­
bectomy. The mismatch volume in this analysis was 
also approximately half that reported in previous 
thrombectomy trials,8,9 which might have reduced the 
potential benefit of reperfusion. For patients with wake­
up stroke, both EXTEND and ECASS4­EXTEND diverged 
from the standard definition of stroke onset (ie, time 
the patient was last known to be well). The treatment 
window for patients with wake­up stroke in EXTEND and 
ECASS4­EXTEND was 9 h after the midpoint of the time 
they fell asleep to the time they woke with symptoms. 
Using the standard definition of onset this led to patients 
being treated up to almost 16 h after the time the patient 
was last known to be well.
The risks of alteplase in the extended time window were 
similar to those for the standard 0–4·5 h treatment 
window. Symptomatic intracranial haemorrhage occurred 
in 4·7% of patients compared with 3·4% in a meta­analysis 
of 0–4·5 h alteplase trials20 using the same definition. Fatal 
intracerebral haemorrhage occurred in 2·3% of patients 
in this analysis compared with 2·6% in the 0–4·5 h data.1 
Automated perfusion mismatch selection did not seem 
to alter the risk of symptomatic intracerebral haemorrhage 
in the alteplase group compared with all patients. However, 
detailed analysis of the cause and timing of death indicated 
that 42 (90%) of 47 deaths were not related to alteplase 
(appendix). No significant difference in the proportion 
of patients with an mRS score of 5 or 6 (death and 
requirement for constant nursing care) was identified 
between treatment groups. The absence of mortality 
benefit with thrombolysis in this analysis is consistent 
with trials of alteplase 0–4·5 h after stroke onset.1
The three trials5,13,18 included in this meta­analysis 
demonstrated consistent treatment effects with mini­
mal heterogeneity. This pooled analysis substantially 
strengthens the results of the EXTEND trial, which 
demonstrated statistically significant improvement in 
excellent functional outcome (mRS score 0–1) and 
functional independence (mRS score 0–2) but did not 
reach significance for the ordinal functional improvement 
outcome. The magnitude of benefit using the ordinal 
outcome indicates that the benefit of increased excellent 
outcome is not offset by an increase in poor outcomes, 
Figure 3: mRS score at 3 months by perfusion mismatch subgroup
mRS score for patients with automated perfusion mismatch (A), and patients without automated perfusion 
mismatch (B). Among patients with mismatch, one patient in the placebo group was excluded because they did not 
have mRS assessment at 3 months. Among patients without mismatch, one patient in the placebo group and 
two patients in the alteplase group were excluded because they did not have mRS assessment at 3 months. Imaging 
data were not available for six patients in the alteplase group and three patients in the placebo group; thus perfusion 
mismatch status could not be determined. mRS=modified Rankin Scale.
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11%
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mRS score
A
B
19%
(n=10) 
9%
(n=4) 
17%
(n=9) 
33%
(n=15) 
9%
(n=5) 
16%
(n=7) 
15%
(n=8) 
16%
(n=7) 
15%
(n=8) 
18%
(n=8) 
8%
(n=4) 
4% (n=2)  
4% (n=2) 
17%
(n=9) 
Placebo 
(n=152)
Alteplase 
(n=152)
Odds ratio 
(95% CI)*
p value
Primary outcome
Excellent outcome (mRS score 0–1) 
at 3 months
39/151 (26%) 55/152 (36%) 2·06 (1·17–3·62) 0·012
Secondary outcomes
Functional improvement in mRS 
score at 3 months†
NA NA 1·68 (1·11–2·53) 0·014
Functional independence 
(mRS score 0–2) at 3 months
60/151 (40%) 77/152 (51%) 2·22 (1·25–3·94) 0·006
Early neurological improvement at 
72 h‡
26/152 (17%) 44/148 (30%) 2·26 (1·26–4·03) 0·006
Safety outcomes
Death at 3 months 16/152 (11%) 20/152 (13%) 1·28 (0·60–2·73) 0·52
Symptomatic intracerebral 
haemorrhage§
1/152 (1%) 7/152 (5%) 7·29 (0·88–60·18) 0·07
Data are n/N (%). mRS=modified Rankin Scale. NIHSS=National Institutes of Health Stroke Scale. NA=not applicable. 
One patient in the placebo group did not have available mRS data at 3 months and thus was excluded from the analysis 
of the primary outcome and selected secondary outcomes. *Adjusted for baseline age and NIHSS. †Reduction of 
≥1 point in mRS score (with mRS categories 5 and 6 merged), analysed using ordinal logistic regression. ‡Reduction of 
≥8 points on NIHSS or reaching NIHSS score 0–1 at 72 h. §Within 36 h of treatment.
Table 4: Study outcomes in patients with automated perfusion mismatch (n=304)
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despite the increase in symptomatic intracerebral 
haemorrhage.
Automated imaging selection was successfully used in 
previous trials8,9 of extended time windows for endo­
vascular thrombectomy and in EXTEND.12 This provides 
objective thresholds to standardise imaging assessment. 
Applying automated processing in this analysis excluded 
around 24% of patients, mostly with small perfusion 
lesions with less than 10 mL mismatch. The analysis 
was underpowered to detect a statistical interaction 
between mismatch status and treatment effect. However, 
the magnitude of difference in point estimates suggests 
that the effect is driven by patients meeting perfusion 
mismatch criteria.
Limitations of this study include the early termination of 
two of the three included trials (EXTEND and ECASS4­
EXTEND), which limited the overall sample size. In both 
trials, however, termination was due to external factors, 
which reduces the potential bias. The requirement for 
perfusion imaging might impede implementation in 
some regions. However, the CT perfusion imaging 
selection used in the majority of patients included in the 
EXTEND trial is more generally available than urgent 
MRI. Automated software is commercially available but 
can be costly in resource­restricted environ ments. Our 
results suggest that automated assessment of mismatch 
is more reliable for the identification of treatment 
responders than visual assess ment, consistent with 
previous studies.21,22 Physician oversight is, however, still 
required for the interpretation of automated output. An 
MRI­based selection approach would allow either the 
diffusion­FLAIR mismatch approach, as used in the 
WAKE­UP trial, or perfusion­diffusion mismatch selec­
tion, which would maximise patient eligibility for alteplase 
treatment. Perfusion mismatch selection allows treatment 
of patients beyond 4·5 h who would be excluded by the 
diffusion­FLAIR approach. However, patients with lacunar 
stroke would not meet perfusion mismatch criteria, but 
were found to benefit from thrombolysis in WAKE­UP.23 
CT perfusion can identify around 50% of patients with 
lacunar stroke,24 but no data are available on thrombolysis 
of lacunar stroke more than 4·5 h from stroke onset based 
on CT perfusion. The trials included in this meta­analysis 
were largely done before the publication of evidence 
supporting endovascular thrombectomy in patients 
with large vessel occlusion 6–24 h after stroke onset. 
Because recruitment largely preceded the evidence for 
thrombectomy, only one patient in this analysis had 
thrombectomy (a protocol violation). However, in current 
practice, 61% of patients in this analysis would now be 
eligible for thrombectomy on the basis of the presence of a 
proximal large vessel occlusion. The combined use of 
thrombolysis and endo vascular thrombectomy in an 
extended time window is currently being investigated in 
an ongoing trial (NCT03785678). However, many insti­
tutions would be capable of delivering thrombolysis 
but not endovascular thrombectomy. In the absence of 
immediate access to endovascular throm bectomy, this 
meta­analysis supports the use of intravenous thrombolysis 
in patients with perfusion mismatch 4·5–9 h from stroke 
onset or with symptoms on waking, regardless of the 
presence of large vessel occlusion. For patients without 
large vessel occlusion, our data expand the proportion of 
patients with ischaemic stroke who can receive reperfusion 
therapies.
In conclusion, alteplase improved functional outcomes 
in patients with acute ischaemic stroke in an extended 
time window when perfusion imaging was favourable. 
The benefit was evident across a range of patient 
subgroups and geographical locations. The risk of symp­
tomatic intracerebral haemorrhage was consistent with 
that observed in previous trials of stroke thrombolysis 
with alteplase in the 0–4·5 h treatment window and did 
not offset the overall benefits in functional outcome. This 
pooled analysis provides strong evidence in support of 
thrombolysis for patients with favourable perfusion 
imaging 4·5–9 h after stroke, including patients with 
wake­up stroke.
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